Hood River Capital Management LLC Buys 19,701 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Hood River Capital Management LLC boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 644,785 shares of the company's stock after purchasing an additional 19,701 shares during the quarter. Hood River Capital Management LLC owned approximately 1.33% of Axsome Therapeutics worth $54,555,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AXSM. Barclays PLC increased its stake in Axsome Therapeutics by 279.6% in the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock worth $5,552,000 after purchasing an additional 45,509 shares in the last quarter. Franklin Resources Inc. raised its holdings in Axsome Therapeutics by 47.5% in the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock worth $13,713,000 after acquiring an additional 51,696 shares during the period. JPMorgan Chase & Co. boosted its stake in Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after purchasing an additional 27,534 shares during the period. Pallas Capital Advisors LLC acquired a new stake in shares of Axsome Therapeutics in the fourth quarter worth $2,237,000. Finally, Flower City Capital bought a new position in Axsome Therapeutics during the fourth quarter valued at about $254,000. Institutional investors and hedge funds own 81.49% of the company's stock.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 22.40% of the company's stock.

Analyst Ratings Changes

AXSM has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price target for the company. Mizuho upped their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. William Blair reaffirmed an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated an "overweight" rating and set a $153.00 target price on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Finally, Wells Fargo & Company lifted their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $169.80.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM traded up $0.78 during mid-day trading on Monday, reaching $107.05. 234,329 shares of the company were exchanged, compared to its average volume of 681,727. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The stock has a market capitalization of $5.22 billion, a PE ratio of -17.87 and a beta of 0.88. The company's 50 day moving average price is $115.54 and its 200 day moving average price is $103.24. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.